Welcome to this exciting new online resource providing you with information and education relating to a long acting medication option available to you for your Child and Adolescent patients with ADHD
This resource will also offer you:
- The ability to order New ADHD Patient Booklets for your surgery*
- A chance to enter a contest to win 1 of 10 copies of 'Developmental-Behavioral Pediatrics: Evidence and Practice'*
PBS Information: Ritalin® LA™ 20, 30 and 40mg. Authority Required for the treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and
who requires continuous coverage over 8 hours. Ritalin® LA™ 10mg. This product is not listed on the PBS |
DRUG DEPENDENCE: Ritalin® should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behaviour. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required
during withdrawal from abusive use since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that may require follow up. |
Please review the ‘Approved Product Information‘ before prescribing this product by clicking on the link. Further information is available on request from Novartis Pharmaceuticals Australia Pty Ltd. ABN 18 004 244 160. 54 Waterloo Road, North Ryde NSW 2113. Ph: (02) 9805 3555. *It is not necessary to grant a Novartis representative an interview in order to receive these items Contest terms & conditions 1. Entry is only open to Medical Practitioners who register on the www.ritalin.net.au website during the competition period. Employees and immediate families of Novartis and their agencies are ineligible to enter. 2. The prize is a Developmental Behavioral Pediatrics: Evidence and Practice Text with CD-ROM. Each Developmental Behavioral Pediatrics: Evidence and Practice Text with CD-ROM is valued at $199. The prize is not transferable or redeemable for cash. 3. Winners will be drawn on the Sunday 30th May at Novartis Australia. 4. The winners will be notified by email by 15th June 2010 with the prize posted out to the winner's nominated postal address. 5. In the event of any dispute, the decision of the promoter is final and binding. No correspondence will be entered into. 6. The competition period is from 30th March 2010 - 30th May 2010. 7. The promoter is Novartis Pharmaceuticals Australia Pty Ltd, 54 Waterloo Road, North Ryde, NSW 2113. ABN 18 004 244 160. Ph. (02) 9805 3555. NSW PERMIT NUMBER: LTPS/10/02502 ACT PERMIT NUMBER: LTPS/10/02774. |